Radiopharmaceutical developer Aktis Oncology priced its IPO at $18 per share, raising roughly $318 million and sending shares sharply higher at debut. The upsized offering and positive market reaction were reported across BioCentury and market briefs. Analysts and bankers framed Aktis’s performance as an early test of 2026’s biotech IPO window: a strong debut could catalyze follow-on listings and revive public market access for drug developers. Aktis is advancing "miniprotein" radioconjugates and holds a discovery partnership with Eli Lilly. The deal’s reception will be monitored closely by companies contemplating public raises and by investors weighing sector re-entry after a muted 2024-25 IPO market.